BioLineRx Ltd.
Long
Zaktualizowano

BLRX-BREAKOUT-UPDATE

389
BLRX had a strong rally today and it's just getting started.

In the related idea my price target was $1.34.

Today's high was $1.78

Check out the weekly chart:

snapshot

Photo Finish.

$1.34 was 1.618 extension level from Waves 1 & 2.

Since the price-action broke $1.34 we will have an extended 3rd wave.

I expect a very strong rally tomorrow, I will update in the morning before the open to confirm.

Target is hard to predict since its impossible to know what level extending waves will terminate.

I will keep a close eye on the price-action.

Will update.

-AB






Uwaga
As expected, a very strong rally today!
Uwaga
snapshot
Uwaga
We got a big runway...
Uwaga
Reminder this is a WEEKLY chart...

Meaning this move is far from over...
Uwaga
snapshot
Uwaga
Buckle up!
Uwaga
snapshot
Uwaga
Target $2.24 (Sell Half)

Trade Price: 1.049
Uwaga
snapshot
Uwaga
snapshot
Uwaga
Bull Flag
Uwaga
BLRX will rally again tomorrow.
Uwaga
snapshot
Uwaga
BLRX is about to rally again...
Uwaga
BLRX continued to consolidate today.

Staying the course...
Uwaga
snapshot
Uwaga
snapshot
Uwaga
Near-Term Target: $2.13
Uwaga
snapshot
Uwaga
Primary Wave 1 Complete
Uwaga
snapshot
Uwaga
03:21 PM EDT, 10/22/2018 (MT Newswires) -- Oppenheimer has kept its outperform rating on BioLineRx (BLRX) with a price target of $3, betting on BL-8040's commercial opportunity as a stem cell mobilizer after top-line data from the COMBAT/KEYNOTE-202 trial of BL-8040 in combination with pembrolizumab in advanced pancreatic cancer showed modest response rate.
"Given the combination's favorable safety profile, BioLineRx and Merck (MRK) are testing a triplet combination including chemotherapy in an effort to increase response rate," analyst Mark Breidenbach said in a note.
"While we believe the triplet combination is worth testing, our valuation of BioLineRx still remains focused on BL-8040's commercial opportunity as a stem cell mobilizer."
Uwaga
snapshot
Uwaga
snapshot
Uwaga
Breakout Imminent
Uwaga
snapshot

Wyłączenie odpowiedzialności

Informacje i publikacje nie stanowią i nie powinny być traktowane jako porady finansowe, inwestycyjne, tradingowe ani jakiekolwiek inne rekomendacje dostarczane lub zatwierdzone przez TradingView. Więcej informacji znajduje się w Warunkach użytkowania.